Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RNASEL | Q05823 | 6/20 | 0.55 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.52 |
| ▸ | P2RY1 | P47900 | 4/20 | 0.51 |
| ▸ | P2RY2 | P41231 | 3/20 | 0.51 |
| ▸ | SRC | P12931 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.51 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.51 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.51 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.51 |
| ▸ | TRPM2 | O94759 | 1/20 | 0.51 |
| ▸ | LDHA | P00338 | 1/20 | 0.51 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.51 |
| ▸ | FBP1 | P09467 | 1/20 | 0.51 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.51 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.51 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.51 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22399293 | 0.93 | RNASEL (0.49) | RNASELP2RX3 | |
| SCHEMBL18510928 | 0.91 | P2RX3 (0.64) | RNASELP2RX3P2RY1P2RY2SRC | |
| SCHEMBL22381588 | 0.89 | RNASEL (0.66) | RNASELADORA1 | |
| SCHEMBL18522261 | 0.86 | RNASEL (0.64) | RNASEL | |
| SCHEMBL21943904 | 0.85 | FUT5 (0.52) | RNASEL | |
| SCHEMBL18521401 | 0.85 | P2RX3 (0.54) | RNASELP2RX3P2RY1P2RY2SRC | |
| SCHEMBL21454748 | 0.85 | FUT5 (0.55) | RNASEL | |
| SCHEMBL21454979 | 0.85 | FUT5 (0.55) | RNASEL | |
| SCHEMBL22399487 | 0.85 | FUT5 (0.50) | RNASEL | |
| SCHEMBL20325280 | 0.85 | FUT5 (0.52) | RNASELP2RY2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10766919-B2 | Cyclic di-nucleotide compounds as sting agonists | MERCK SHARP & DOHME CORP. (US) | 2020-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10766919-B2 | Cyclic di-nucleotide compounds as sting agonists | STING1, CGAS, IFNAR1 | RNASEL 574/4885P2RX3 127/4885P2RY1 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.